Cell surface antigens in leukemias and lymphomas

Cancer Investigation

Volumn 14, Issue 3, 1996, Pages 252-276

  Freedman, Arnold S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN;

HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKEMIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0029764085     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609012148     Document Type: Review

References (354)

1. Brouet JC, Preud'homme JL, Penit C, Valensi F, Rouget P, Seligmann M: Acute lymphoblastic leukemia with pre-B cell characteristics. Blood 54:269, 1979.
2. Korsemeyer JS, Arnold A, Bakhshi A, Ravetch JV, Siebenlist V, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldman TA: Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest 71:301, 1983.
3. Nadler LM, Anderson KC, Marti G, Bates M, Paark E, Daley JF, Schlossman SF: B4, a human B cell associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J Immunol 131:244, 1983.
4. Tedder TF, Isaacs C: Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: A new member of the immunoglobulin superfamily. J Immunol 143:712, 1989.
5. Stamenkovic I, Seed B: CD19, the earliest differentiation antigen of B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus related cytoplasmic tail. J Exp Med 168:1205, 1988.
6. Carter R, Tuveson D, Park D, Rhee S, Fearon D: The CD19 complex of lymphocytes: Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 147:3663, 1991.
7. Strauss LC, Civin CI: MY10, a human progenitor cell surface antigen identified by a monoclonal antibody. Exp Hematol 11 (Suppl 14):370, 1983.
8. Hurwitz CA, Loken MR, Graham ML, Kzarp JE, Borowitz MJ, Pullen DJ, Civin CI: Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 72:299, 1988.
9. He X, Antao V, Basila D, Marx J, Davis B: Molecular characterization of the human CD34 gene. Blood 78:371, 1991.
10. Dorken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, Nadler LM: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470, 1986.
11. Stamenkovic I, Seed B: The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 345:74, 1990.
12. Cossman J, Neckers LM, Arnold A, Korsmeyer SJ: Induction of differentiation in a case of common acute lymphoblastic leukemia. N Engl J Med 307:1251, 1982.
13. Hokland P, Rosenthal P, Griffin J, Nadler LM, Daley JF, HoKland M, Schlossman SF, Ritz J: Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med 157:114, 1983.
14. Nadler LM, Ritz J, Bates MP, Park EK, Anderson KC, Sallan SE, Schlossman SF: Induction of human B cell antigen in non-T cell acute lymphoblastic leukemia. J Clin Invest 70:433, 1982.
15. Shipp MA, Richardson NE, Sayre PH, Brown NR, Masteller EL, Clayton LK, Ritz J, Reinherz EL: Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci USA 85:4819, 1988.
16. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL: Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): Direct evidence by cDNA transfection analysis. Proc Natl Acad Sci USA 86:297, 1989.
17. Salles G, Reinherz E, Shipp M: CD10/NEP inhibition potentiates stromal cell dependent lymphopoeisis. Blood 78:158, 1991.
18. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711, 1988.
19. Stamenkovic I, Seed B: Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1,Bp35), a type III integral membrane protein. J Exp Med 167:1975, 1988.
20. Tedder TF, Streuli M, Schlossman SF, Saito H: Isolation and structure of a cDNA encoding the B1 (CD20) cell surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 85:208, 1988.
21. Tedder TF, Boyd AW, Freedman AS, Nadler LM: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973, 1985.
22. Clark EA, Shu G, Ledbetter JA: Role of the Bp35 cell surface polypeptide on human B-cell activation. Proc Natl Acad. Sci USA 82:1766, 1985.
23. Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T: Triggering of neoplastic B cells via surface IgM and the cell surface antigen CD20 and CDw40: Responses differ from normal blood B cells and are restricted to certain morphologic subsets. Int J Cancer 42:521, 1988.
24. Tedder TF, Bell PD, Frizzell RA, Bubien JK: CD20 directly regulates transmembrane ion flux in B lymphocytes. Tissue Antigen 33:145, 1989.
25. Morimoto C, Letvin NL, Boyd AW, Hagan M, Brown HM, Kornacki MM, Schlossman SF: The isolation and characterization of the human helper inducer T cell subset. J Immunol 134:3762, 1985.
26. Hemler ME: VLA proteins in the integrin family: Structure, functions, and their role on leukocytes. Annu Rev Immunol 8:365, 1990.
27. Ryan D, Nuccie B, Abboud C, Winslow I: Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 88:995, 1991.
28. Clark EA, Ledbetter JA: Structure, Function, and Genetics of Human B Cell-Associated Surface Molecules. New York, Academi Press, 1989.
29. Braesch-Anderson S, Paulie S, Aspenstrom P, Koho H, Perlmann P: Biochemical characteristics of the human B-cell and carcinoma antigen Cdw40. Tissue Antigens 33:129, 1989.
30. Inui S, Kaisho T, Clark EA, Seed B, Kikutani H, Kishimoto T: Expression of intact and mutant CDw40 on murine lymphocytes (cytoplasmic portion is essential for signal transduction through CDw40). Tissue Antigens 33:133, 1989.
31. Uckun F, Ledbetter JA: Expression and function of CDw40/Bp50 antigen in early human B-lymphocyte ontogeny. Tissue Antigens 33:146, 1989.
32. Cairns J, Flores-Romo L, Millsum MJ, Guy GR, Gillis S, Ledbetter JA, Gordon J: Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CD40). Eur J Immunol 18:349, 1988.
33. Liu Y-J, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan ICM: Mechanism of antigen-driven selection in germinal centres. Nature 342:929, 1989.
34. Morimoto C, Letvin N, Distaso J, Aldrich W, Schlossman S: The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 134:1508, 1985.
35. Ritter MA, Sauvage CA, Pegram SM, Myers CD, Dalchau R, Fabre JW: The human leukocyte-common (LC) molecule: Dissection of leukemias using monoclonal antibodies directed against framework and restricted antigenic determinants. Leuk Res 9:1249, 1985.
36. Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H: Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med 166: 1548, 1987.
37. Charbonneau H, Tonks NK, Walsh KA, Fischer EH: The leukocyte common antigen (CD45): A putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci USA 85:7182, 1988.
38. Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J: Expression of a 26,000 dalton glycoprotein on activated human T cells. Cell Immunol 64:192, 1981.
39. Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M: A human hemopoietic progenitor and acute lymphoblastic leukemia-associated cell surface structure identified with a monoclonal antibody. J Exp Med 153:726, 1981.
40. Abramson C, Kersey JR, LeBien TW: A monoclonal antibody (BA-1) primarily reactive with cells of human B lymphocyte lineage. J Immunol 126:83, 1981.
41. Fischer G, Majdic O, Gadd S, Knapp W: Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 144:638, 1990.
42. Boumsell L, Coppin H, Pham D, Raynal B, Lemerle J, Dausset J, Bernard A: An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. J Exp Med 152:229, 1980.
43. Jones NH, Clabby ML, Dialynast DP, Huang H-JS, Herzenberg LA, Strominger JL: Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature 323:346, 1986.
44. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P: Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cell. J Immunol 135:2331, 1985.
45. Van de Velde H, von Hoegen I, Luo W, Parnes J, Thielmans K: The B cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 351:662, 1991.
46. Gowans JL, Knight EJ: The route of recirculation of lymphocytes in the rat. Proc R Soc Lond (Biol) 159:257, 1964.
47. Stamper HB, Woodruff JJ: Lymphocyte homing into lymph nodes: In vitro demonstration of the selective affinity of recirculating lymphocytes for high endothelial venules. J Exp Med 144:828, 1976.
48. Gallatin WM, Weissman IL, Butcher EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 304:30, 1983.
49. Goldstein LA, Zhou DFH, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC: A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 56:1063, 1989.
50. St. John T, Meyer J, Idzerda R, Gallatin WM: Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60:45, 1990.
51. Stamemkovic I, Amiot M, Pesando JM, Seed B: A lymphocyte molecule implicated in lymph node homing is a member of the catilage link protein family. Cell 56:1057, 1989.
52. Stoolman LM: Adhesion molecules controlling lymphocyte migration. Cell 56:907, 1989.
53. Tedder TF, Isaacs CM, Ernst TJ, Demetri GD, Adler DA, Disteche CM: Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1 : Homology with the mouse lymphocyte homing receptor and other human adhesion proteins. J Exp Med 170:123, 1989.
54. Camerini D, James SP, Stamenkovic I, Seed B: Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor. Nature 342:78, 1989.
55. Siegelman MH, Van De Rijn M, Weissman IL: Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science 243:1165, 1989.
56. Spertini O, Kansas G, Munro J, Griffin J, Tedder T: Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1)selectin. Nature 349:691, 1991.
57. Meidema F, Tromp JF, Veer MB, Poppema S, Melief CJM: Lymphocyte function-associated antigen 1 (LFA-1) is a marker of mature (immunocompetent) lymphoid cells: A survey of lymphoproliferative disease in man. Leuk Res 9:1099, 1985.
58. Campana D, Sheridan B, Tidman N, Hoffbrand AV, Janossy G: Human leukocyte fuction-associated antigens on lymphohematopoetic precurser cells. Eur J Immunol 16:537, 1986.
59. Springer TA: Adhesion receptors of the immune system. Nature 346:425, 1990.
60. Albelda SM, Buck CA: Integrins and other cell adhesion molecules. FASEB J 4:2868, 1990.
61. Rothlein R, M.L. D, Marlin SD, Springer TA: A human intracellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270, 1985.
62. Marlin SD, Pringer TA: Purified intracellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte-functional antigen 1 (LFA-1). Cell 51:813, 1987.
63. Mentzer SJ, Gromkowski SH, Krensky AM, Burakoff SJ, Martz E: LFA-1 membrane molecule in the regulation of homotypic adhesion of human B lymphocytes. J Immunol 135:9, 1985.
64. Patarroyo M, Clark EA. Prieto J, Kantor C, Gahmberg CG: Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2. FEBS Lett 210:127, 1987.
65. Patarroyo M, Prieto J, Betty PG, Clark EA, Gahmberg CG: Adhesion-mediating molecules of human monocytes. Cell Immunol 113:278, 1988.
66. Prieto J, Beatty PG, Clark EA, Patarroyo M: Molecules mediating adhesion of T and B cells, monocytes and granulocytes to vascular endothelial cells. Cell Immunol 63:631, 1988.
67. Koopman G, Parmentier HK, Schuurman H-K, Newman W, Meijer CJLM, Pals S: Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intracellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways. J Exp Med 173: 1297, 1991.
68. Rice GE, Bevilacqua MP: An inducible endothelial cell surface glycoprotein mediates melenoma adhesion. Science 246:1303, 1989.
69. Freedman AS, Munro MJ, Rice GE, Bevilacqua MP, Morimoto C, McIntyre BW, Rhynhart K, Pober JS, Nadler LM: Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 249:1030, 1990.
70. Iida K, Nadler LM, Nussenzweig V: The complement fragment C3d is a ligand for the human B lymphocyte membrane antigen B2. J Exp Med 158:1021, 1983.
71. Fingerroth JD, Weis J, Tedder TF, Strominger JL, Biro PA, Fearon DT: Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 81:4510, 1984.
72. Nadler LM, Boyd AW, Park E, Anderson KC, Fisher D, Slaughenhoupt B, Thorley-Lawson DA, Schlossman SF: The B Cell-Restricted Glycoprotein (B2) Is the Receptorfor Epstein-Barr Virus. New York, Springer-Verlag, 1986.
73. Iida K, Nadler LM, Nussenzweig V: The identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 158:1021, 1983.
74. Haynes B, Hemler BF, Cotner T, Mann DL, Eisenberth GS, Strominger JL, Fauci AS: Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol 127:347, 1981.
75. Haynes BF, Hemler ME, Mann DL, Eisenberth GS, Shelhamer J, Mostowski HS, Thomas CA, Strominger JL, Fauci AS: Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 126: 1409, 1981.
76. Tsudo M, Uchiyama T, Uchino H: Expression of TAC antigen on activated normal human B cells. J Exp Med 160:612, 1984.
77. Boyd AW, Fisher DC, Fox D, Schlossman SF, Nadler LM: Structural and functional characterization of II-2 receptors on activated B cells. J Immunol 134:2387, 1985.
78. Miller RA, Gralow J: The induction of Leu-1 antigen expression in human malignant and normal B cells by phorbol myristic acetate (PMA). J Immunol 133:3408, 1984.
79. Freedman AS, Boyd AW, Bieber F, Daley J, Rosen K, Horowitz J, Levy D, Nadler LM: Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 70:418, 1987.
80. Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Nadler LM: Studies on in vitro activated CDS+ B cells. Blood 73:202, 1989.
81. Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H, Nadler LM: Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol 19:849, 1989.
82. Wemer-Favre C, Vischer T, Wohlwend D, Zubler R: Cell surface CDS is a marker for activated human B cells. Eur J Immunol 19:1209,1989.
83. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM: B7, a B cell restricted antigen which identifies pre-activated B cells. J Immunol 137:3260, 1987.
84. Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB1) expressed on Epstein-Barr virus-activated B cell blasts. B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 128:823, 1982.
85. Thorley-Lawson DA, Nadler LM, Bhan A, Schooley RT: Blast-2 (EBVCS): An early cell surface marker of human B cell activation is superinduced by Epstein-Barr virus. J Immunol 134:3007, 1985.
86. Murray LJ, Habeshaw JA, Wiels J, Greaves MF: Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer 36:561, 1985.
87. Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF, Nadler LM: B5, a new B cell restricted activation antigen. J Immunol 134:2228, 1985.
88. Defrance T, Aubry JP, Rousset F, Vanberulist B, Bonnefoy JY, Arai N, Takebe Y, Yokota T, Lee F, Aral K, DeVries J, Banchereau J: Human recombinant interleukin 4 induces FcE receptors (CD23) on normal human B lymphocytes. J Exp Med 165:1459, 1987.
89. Gordon J, Rowe M, Walker L, Guy G: Ligation of the CD23 p45 antigen triggers cell-cycle progression of activated B lymphocytes. J Immunol 16:1075, 1986.
90. Ikuta K, Takami M, Kim CW, Honjo T, Miyoshi T, Tagaya Y, Kawabe T, Yodoi J: Human lymphocyte Fc receptor for IgE: Sequence homology of its cloned cDNA with animal lectins. Proc Natl Acad Sci USA 84:819, 1987.
91. Kikutani H, Inui S, Sato R, Barsumain LE, Owaki H, Yamaski K, Kaisho T, Uchibayshi N, Hardy RR, Hirano T, Tsunasawa S, Sakiyama F, Suemura M, Kishimato T: Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell 47:657, 1986.
92. Clark EA, Yokochi T: Human B Cell and B Cell Blast-Associated Surface Molecules Defined with Monoclonal Antibodies. Leukocyte Typing I. Berlin, Springer Verlag, 1984.
93. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714, 1989.
94. Linsley PS, Clark EA, Ledbetter JA: T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 87:5031, 1990.
95. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB: T-cell proliferation involving the CD28 pathway is associated with cyclosporin-resistant interleukin 2 gene expression. Mol Cell Biol 7:4472, 1987.
96. Thompson CB, Lindsten T, Ledbetter JA, S.L. K, Young HA, Emerson SG, Leiden JM, June CH: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 86:1333, 1989.
97. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activalion. Immunol Today 58:271, 1990.
98. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, Thompson CB, June CH: CD28 ligation in T-cell activation: Evidence for two signal transduction pathways. Blood 75:1531, 1990.
99. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B7 provides acostimulatory signal which induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 88:6575, 1991.
100. Kishimoto T: Factors affecting B cell growth and differentiation. Annu Rev Immunol 3:133, 1985.
101. Stamenkovic I, Seed B: Molecular cloning of CD38. Tissue Antigens 33:139, 1989.
102. Anderson KC, Park K, Bates M, Leonard RCF, Hurdy R, Schloosman SF, Nadler LM: Antigens on human plasma cells identified by monoclonal antibodies. J Immunol 130:1132, 1983.
103. Moore MAS, Owen JT: Experimental studies on the development of the thymus. J Exp Med 126:715, 1967.
104. Reinherz EL, Schlossman SF: The differentiation and function of human T lymphocytes: A review. Cell 19:821, 1980.
105. Jackson D, Bell J: Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 144:2811, 1990.
106. Pawelec A, Rehbein I, Balko U, Reusch K, Schaudt H, Buehring J: Stimulatory Capacity of Workshop T Cell Antibodies on T Lymphocyte Clones. Copenhagen, Munksgaard, 1989.
107. Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA: The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 326:400, 1987.
108. Meuer S, Hussey R, Fabbi M, Fox D, Acuto O, Fitzgerald K, Hodgdon J, Protentis J, Schlossman S, Reinherz E: An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36:897, 1984.
109. Terhorst C, van Agthoven A, LeClair K, Ledbetter JA, Moldenhauer G, Clark EA: Biochemical studies in the human thymocyte antigens T6, T9, and T10. Cell 23:771, 1981.
110. Amiot M, Dastot H, Schmid M, Bernard A, Boumsell L: Analysis of CD1 molecules on thymus cells and leukemic T lymphoblasts identifies discrete phenotypes and reveals that CD1 intermolecular complexes are observed only on normal cells. Blood 70:676, 1987.
111. McMichael AJ, Gotch FM: T-cell antigens: New and Previously Defined Clusters. Oxford, Oxford University Press, 1987.
112. Rudd CE, Trevillyan JM, Dasgupta JD, Wong LL, Schlossman SF: The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc Natl Acad Sci USA 85:5190, 1988.
113. Barber EK, Dasgupta JD, Schlossman SF, Trevillyan JM, Rudd CE: The CD8 antigen is coupled to a protein-tyrosine kinase (p58 Lck) that phosphorylates the CD3 complex in vitro. Tissue Antigens 33:93, 1989.
114. Campana D, Thompson JS, Amlot P, Brown S, Janossy G: The cytoplasmic expression CD3 antigens in normal and malignant cells of T lymphoid lineage. J Immunol 138:648, 1987.
115. Acuto O, Reinherz EL: The human T-cell receptor: Structure and function. N Engl J Med 312:1100, 1985.
116. Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, Ip S, Rosen F, Krangel MS: Identification of a putative second T-cell receptor. Nature 322:145, 1986.
117. Uchiyama T, Broder S, Waldmann TA: A monoclonal antibody (anti-TAC) reactive with activated and functionally mature T cells. I. Production of anti-TAC monoclonal antibody and distribution of Tac (+) cells. J Immunol 126:1393, 1981.
118. Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF: Tal, a novel 105 kd human T cell activation antigen defined by a monoclonal antibody. J Immunol 133:1250, 1984.
119. Griffin JD, Linch D, Sabbath KD, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal leukemic human myeloid progenitor cells. Leuk Res 8:521, 1984.
120. Sakai K, Hattori T, Sagawa K, Yokoyama M, Takatsuki K: Biochemical and functional characterization of MCS-2 antigen (CD13) on myeloid leukemic cells and polymorphonuclear leukocytes. Cancer Res 47:5572, 1987.
121. Griffin JD, Ritz J, Nadler LM, Schlossman SF: Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 68:932, 1981.
122. Griffin JD, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF: Expression of MY7 antigen on myeloid progenitor cells. Int J Cell Cloning 1:33, 1983.
123. Lewinsohn D, Nagler A, Ginzton N, Greenberg P, Butcher E: Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 75:589, 1990.
124. Look AT, Ashmun RA, Shapiro LH, Peiper SC: Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 83:1299, 1989.
125. Symington F, McMaster B, Hakomori S, Bernstein I: Glycolipid Specificities of Anti-hematopoietic Cell Antibodies. Leukocyte Typing II. New York, Springer-Verlag, 1986.
126. Arnaout MA, Todd RF, Dana N, Melaned J, Schlossman SF, Colter HR: Inhibition of phagocytes of complement C3 or IgG coated particles and of C3Bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol). J Clin Invest 72:171, 1983.
127. Dudley D, Baker D, Hickey M, Hickstein D: Expression of surface antigen and mRNA for the CD11c (alpha X, p150) subunit of the human leukocyte adherence receptor family in hematopoietic cells. Biochem Biophys Res Commun 160:346, 1989.
128. Simmons D,Tan S, Tenen D, Nicholson-Weller A, Seed B: Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 73:284, 1989.
129. Sobol RE, Roystan I, LeBien T, Minowada J, Anderson K, Davey FR, Cuttner J, Schiffer C, Ellison RR, Bloomfield CD: Adult lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood 65:730, 1985.
130. Vaughan WP, Civin CI, Weisenburger DD, Karp JE, Graham ML, Sanger WG, Gierson HL, Joshi SS, Burke PJ: Acute leukemia expressing the normal hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia 2:661, 1988.
131. Batinic D, Tindle R, Boban D, Tiefenbach A, Rajic L, Labar B, Nemet D, Boranic M: Expression of haematopoietic progenitor cell-associated antigen BI-3C5/CD34 in leukemia. Leuk Res 13:83, 1989.
132. Borowitz M, Shuster J, Civin C, Carroll A, Look A, Behm F, Land V, Pullen D, Crist W: Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 8:1389, 1990.
133. Vogler LC, Crist WM, Bockman DE, Pearl ER, Lawton AR, Cooper MD: Pre-B cell leukemia; a new phenotype of childhood lymphoblastic leukemia. N Engl J Med 298:872, 1978.
134. Nadler LM, Stashenko P, Ritz J, Hardy R, Pesando JM, Schlossman SF: A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 67:134, 1981.
135. Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, Jensen J, Coral F, Mayer RJ, Sallen SE, Ritz J, Schlossman SF: B cell origin of non-T cell acute lymphoblastic leukemia. J Clin Invest 74:332, 1984.
136. Janossy G, Coustan-Smith E, Campana D: The reliability of cytoplasmic CD3 and Cd22 antigen expression in the immunodiagnosis of acute leukemia: A study of 500 cases. Leukemia 3:170, 1989.
137. Hoelzer D, Thiel E, Loeffer H, Buechner T, Ganser A, Heil G, Koch P, Freud M, Diedrich H, Ruehl H, Machmeyer G, Lipp T, Nowrousion MR, Burkert M, Gerecke D, Pralle H, Mueller U, Lunscken C, Fuelle H, Ao AD, Kuechler R, Busch RW, Schneider W, Goerg C, Emmerich B, Brauman D, Vaupel HA, von Paleske A, Bartels H, Neiss A, Messerer D: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123, 1988.
138. Pui CH, Williams DL, Raimondi SC, Melvin SL, Behm FG, Look AT, Dahl GV, Rivera GK, Kalvinsky DK, Mirro J, Dodge RK, Murphy SB: Unfavorable presenting clinical and laboratory features are associated with Calla-negative non-T, non-B lymphoblastic leukemia in children. Leuk Res 10:1287, 1986.
139. Katz F, Malcom S, Gibbons B, Tilly R, Lam G, Robertson ME, Czepulkowski B, Chessells J: Cellular and molecular studies on infant null acute lymphoblastic leukemia. Blood 71:1438, 1988.
140. Dinndorf PA, Andrews RG, Benjamin D, Ridgeway D, Wolff L, Bernstein ID: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67:1048, 1986.
141. Behm F, Raimondi S, Schell M, Look A, Rivera G, Pui C: Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood 79:1011, 1992.
142. Pui C, Hancock M, Head D, Rivera G, Look A, Sandlund J, Behm F: Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 82:889, 1993.
143. Kersey JH, Sabad A, Gajl-Peczalska F, Haligne HM, Yunis EJ, Nesbit ME: Acute lymphoblastic leukemic cells with T (thymus-derived) lymphoma markers. Science 182:1355, 1973.
144. Mosalayi MD, Bertho JM, Dalloul AH, Lecron JC, Debre P: CD7 is the earliest cell surface antigen detected on T cell lineage. Tissue Antigens 33:108, 1989.
145. Lo Coco F, De Rossi G, Pasqualetti D, Lopez M, Diverio D, Latagliata R, Fenu S, Mandelli F: CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Haematol 73:480, 1989.
146. Tien H, Wang C, Su I, Liu F, Wu H, Chen Y, Lin K, Lee S, Shen M: A subset of acute nonlymphocytic leukemia with expression of surface antigen CD7 - Morphologic, cytochemical, immunocytochemical and T cell receptor gene analysis on 13 patients. Leuk Res 14:515, 1990.
147. Jensen A, Hokland M, Jorgensen H, Justesen J, Ellegaard J, Hokland P: Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: Identification of a group of patients with similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood 78:1292, 1991.
148. Eto T, Akashi K, Harada M, Shibuya T, Takamatsu Y, Teshima T, Niho Y: Biological characteristics of CD7 positive acute myelogenous leukaemia. Br J Haematol 82:508, 1992.
149. Reinherz EL, Nadler LM, Sallen SE, Schlossman SF: Subject derivation of T-cell acute lymphoblastic leukemia in man. J Clin Invest 64:392, 1979.
150. Mirro J, Kitchingman G, Behm FG, Murphy SB, Goorha RM: T cell differentiation stages identified by molecular and immunologic analysis of the T cell receptor complex in childhood lymphoblastic leukemia. Blood 69:908, 1987.
151. Kurtzberg J, Waldmann T, Davey M, Bigner S, Moore J, Hershfield M, Haynes B: CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells. Blood 73:381, 1989.
152. Thiel E, Kranz B, Raghavachar A, Bartram C, Loffler H, Messerer D, Ganser A, Ludwig W, Buchner T, Hoelzer D: Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 73:1247, 1989.
153. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE: Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group study. Blood 72:1891, 1988.
154. Link MP, Stewart SJ, Warnke RA, Levy R: Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. J Clin Invest 76:248, 1985.
155. Van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, Comans-Bitter WM, Adriaansen HJ, Hooijkaas H, van Wering ER, Terhorst C: Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood 71: 603, 1988.
156. Pui C, Behm F, Singh B, Rivera G, Schell M, Roberts W, Crist W, Mirro JJ: Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75:198, 1990.
157. Morabito F, Prasthofer EF, Pullen DJ, Mahoney D, Downing JR, Crist WM, Grossi CE: Analysis of surface antigen profile, TdT expression, and T cell receptor gene rearrangement for maturational staging of leukemic T cells: A Pediatric Oncology Group study. Leukemia 1:514, 1987.
158. Ledbetter JA, Uckun FM: Expression of a functional CD3-T-cell receptor complex on leukemic human T-cell precursers. Tissue Antigens 33:88, 1989.
159. Pui CH, Dahl GV, Melvin S, Williams DL, Peiper S, Mirro J, Murphy SB, Stass S: Acute leukaemia with mixed lymphoid and phenotype. Br J Haematol 56:121, 1984.
160. Davey FR, Mick R, Nelson DA, MacCullum J, Sobol RE, Royston I, Cuttner J, Ellison RR, Bloomfiel CD: Morphologic and cytochemical characterization of adult lymphoid leukemias which express myeloid antigen. Leukemia 2:420, 1988.
161. Bradstock K, Kirk J, Grimsley P, Kabral A, Hughes W: Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations. Br J Haematol 72:512, 1989.
162. Urbano-Ispizua A, Matutes E, Villamor N, Ribera J, Feliu E, Montserrat E, Granena A, Vives-Corrons J, Rozman C: Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. Br J Haematol 75:202, 1990.
163. Pui C, Behm F, Singh B, Schell M, Williams D, Rivera G, Kalwinsky D, Sandlund J, Crist W, Raimondi S: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174, 1990.
164. Wiersma S, Ortega J, Sobel E, Weinberg K: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 324:800, 1991.
165. Guyotat D, Campos L, Shi Z, Charrin C, Treille D, Magaud J, Fiere D: Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia 4:664, 1990.
166. Uckun FM, Muraguchi A, Ledbetter JA, Kishimoto T, O'Brien RT, Roloff JS, Gajl-Peczalska K, Provisor A, Koller B: Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 73:1000, 1989.
167. Akashi K, Shibuya T, Harada M, Morioka E, Oshima K, Kimura N, Takeshita M, Kurokawa M, Kikuchi M, Niho Y: Acute "bilineal-biphenotypic" leukaemia. Br J Haematol 74: 402, 1990.
168. Campana D, Hansen-Hagge T, Matutes E, Coustan-Smith E, Yokota S, Shetty V, Bartram C, Janossy G: Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. Leukemia 4:620, 1990.
169. Griffin JD, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, Schlossman SF: Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation-associated phenotypes. Blood 62:557, 1983.
170. Drexler HG, Sagawa K, Menon M, Minowada J: Reactivity pattern of "myeloid monoclonal antibodies" with emphasis on MCS-2. Leuk Res 10:17, 1986.
171. Katz FE, Tindle R, Sutherland DR, Greaves MF: Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. Leuk Res 9:191, 1985.
172. Majdi O, Bettelheim P, Stockinger H, Aberer W, Liska K, Lutz D, Knapp W: M2, a novel myelomonocytic cell surface antigen and its distribution on leukemic cells. Int J Cancer 33:617, 1984.
173. Borowitz M, Gockerman J, Moore J, Civin C, Page S, Robertson J, Bigner S: Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 91:265, 1989.
174. Soligo D, Delia D, Oriani A, Cattoretti G, Orazi A, Bertolli V, Quirici N, Deliliers G: Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monclonal antibody. Leukemia 5:1026, 1991.
175. Iizuka Y, Aiso M, Oshimi K, Kanemaru M, Kawamura M, Takeuchi J, Horikoshi A, Ohshima T, Mizoguchi H, Horie T: Myeloblastoma formation in acute myeloid leukemia. Leuk Res 16:665, 1992.
176. Ikushima S, Yoshihara T, Matsumura T, Misawa S, Morioka Y, Hibi S, Imashuku S: Expression of CD56/NCAM on hematopoietic malignant cells: A useful marker for acute monocytic and megakaryocytic leukemias. Int J Hematol 54:395, 1991.
177. Palucka A, Porwit A, Reizenstein P: A supportive role of neural cell adhesion molecule (NCAM) in adhesion between leukaemic blasts and cytotoxic lymphocytes. Scand J Immunol 35:399, 1992.
178. Liesveld J, Winslow J, Frediani K, Ryan D, Abboud C: Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 81:112, 1993.
179. Denkers I, de Jong-de Boer T, Beelen R, Ossenkoppele G, Langenhuijsen M: VLA molecule expression may be involved in the release of acute myeloid leukaemic cells from the bone marrow. Leuk Res 16:469, 1992.
180. Ball ED, Fanger MW: The expression of myeloid-specific antigens on myeloid leukemia cells: Correlations with leukemia subclasses and implications for normal myeloid differentiation. Blood 61:456, 1983.
181. Linch DC, Allen C, Beverley PCL, Bynoe AG, Scott CS, Hogg N: Monoclonal antibodies differentiating between monocytic and nonmonocytic varients of AML. Blood 63:566, 1984.
182. Neame PB, Soamnoonsrup P, Browman GP, Mayer RM, Benger A, Wilson WEC, Walker IR, Saeed N, McBride JA: Classifying acute leukemia by immunophenotyping: A combined FAB-immunologic classification of AML. Blood 67:1355-1362, 1986.
183. Bettelheim P, Panzer S, Majdic O, Stockinger H, Roithner A, Koeller U, Meryn S, Lechner K, Knapp W: Unexpected absence of a myeloid surface antigen (3-fucosyl-n-acetyllactosamine) in promyelocytic leukemia. Leuk Res 9:1323, 1985.
184. Das Gupta A, Dhond SR: Phenotypic heterogeneity of erythroblasts in erythroblastic leukemia revealed by monoclonal antibodies. Am J Hematol 29:12, 1989.
185. San Miguel JF, Gonzales M, Canizo MC, Anta JP, Zola H, Lopez A, Borrasca A: Surface markers analysis in AML and correlation with FAB classification. Br J Hematol 64:547, 1986.
186. Imamura N, Mtasiwa D, Ota H, Inada T, Kuramoto A: Distribution of cell surface glycoprotein CD9 (P24) antigen on megakaryocyte lineage leukemias and cell lines. Am J Hematol 35:65, 1990.
187. Matolcsy A, Kalman E, Pajor L, Konya T, Weber E: Morphologic and flow cytometric analysis of circulating megakaryoblasts in chronic myeloid leukaemia. Leuk Res 15:887, 1991.
188. Erber WN, Breton-Gorius J, Villeval JL, Oscier DG, Bai Y, Mason DY: Detection of cells of megakaryocyte lineage in hematological malignancies by immuno-alkaline phosphatase labelled smears with a panel of monoclonal antibodies. Br J Hematol 65:87, 1987.
189. Koike T, Aoki S, Maruyama S, Narita M, Ishizuka T, Imanaka H, Adachi T, Maeda H, Shibata A: Cell surface phenotyping of megakaryoblasts. Blood 957-960:1987.
190. Varon D, Gittel S, Linder S, Bassous-Guedj L, Vorst E, Berrebi A: an antiplatelet glycoprotein IIb monoclonal antibody (3B2) interacts with activated platelets and recognizes immature megakaryoblasts. Tissue Antigens 33:347, 1989.
191. Civin CI, Vanghan WP, Straa LC, Schwartz JF, Karp JE, Burke PJ: Diagnostic and prognostic utility of cell surface markers in acute non-lymphocytic leukemia (ANLL). Exp Hematol 11 (Suppl 14): 152, 1983.
192. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D: Surface marker expression in adult acute myeloid leukaemia: Correlations with initial characteristics, morphology and response to therapy. Br J Haematol 72:161, 1989.
193. Myint H, Lucie N: The prognostic significance of the CD34 antigen in acute myeloid leukaemia. Leuk Lymphoma 7:425, 1992.
194. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD: Use of surface marker analysis to predict outcome of adult myeloblastic leukemia. Blood 68:1232, 1986.
195. Schwarzinger I, Valent P, Koller U, Knapp W, Lechner K, Bettelheim P: Prognostic significance of surface marker scpression on blasts of patients with acute myeloid leukemia. Tissue Antigens 33:245, 1989.
196. Pikington GR, Wolf MM, Matthews J, Griffiths JD, Cooper IA, Forster DC, Jose DG: Correlation of CD surface antigen phenotype with FAB subtype remission induction and survival in AML patients. Tissue Antigens 33.243, 1989.
197. Merle-Beral H, Nguyen Cong Due L, Leblond V, Boucheix C, Michel A, Chastang C, Debre P: Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia. Br J Haematol 73:323, 1989.
198. Tucker J, Dorey E, Gregory W, Simpson A, Amess J, Lister T, Horton M: Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 8:47, 1990.
199. Dinndorf P, Buckley J, Nesbit M, Lampkin B, Piomelli S, Feig S, Kersey J, Hammond G, Bernstein I: Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: Increased concentration of CD33 antigen predicts poor outcome - A report from the Childrens Cancer Study Group. Med Pediatr Oncol 20: 192, 1992.
200. Ball E, Davis R, Griffin J, Mayer R, Davey F, Arthur D, Wurster-Hill D, Noll W, Elghetany M, Allen S: Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77: 2242, 1991.
201. Pui C, Raimondi S, Head D, Schell M, Rivera G, Mirro J, Crist W, Behm F: Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 78:1327, 1991.
202. Kuerbitz S, Civin C, Krischer J, Ravindranath Y, Steuber C, Weinstein H, Winick N, Ragab A, Gresik M, Crist W: Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:1419, 1992.
203. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Monta N, Takakura N, Otsuji A, Shirakawa S, Ueda T: Phenotypical characteristics of acute myelocytic leukemia associated with the t(8; 21)(q22; q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 80:1992:470, 1992.
204. Uchiyama T, Hori T, Tsudo M, Wano Y, Umadome H, Tamori S, Yodoi J, Maeda M, Sawami H, Uchino H: Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 76:446, 1985.
205. Dallenbach F, Josimovic-Alasevic O, Durkop H, Schwarting R, Pizzolo G, Diamantstein T, Takasuki K, Stein H: Soluble Ki-1 (CD30) antigen in the sera of patients with adult T cell lymphoma/leukemia: A marker of disease activity. Tissue Antigens 33:309, 1989.
206. Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayney DW, Blattner WA, Goldman CK, Bongiovanni K, Sharrow S, Depper JM, Leonard W, Uchiyama T, Gallo RC: Functional and phenotyping comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. J Clin Invest 73:1711, 1984.
207. Hoshino S, Oshimi K, Tsudo M, Miyasaka M, Teramura M, Masuda M, Motoji T, Mizoguchi H: Flow cytometric analysis of expression of interleukin-2 receptor beta chain (p70-75) on various leukemic cells. Blood 76:767, 1990.
208. Fukunaga Y, Evans S, Yamamoto M, Ueda Y, Tamura K, Takakuwa T, Gebhard D, Allopenna J, Demaria S, Clarkson B: Increased density of ecto 5′ nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Blood 74:2486, 1989.
209. Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K: Profiles of expression of activated cell antigens on peripheral blood and lymphnode cells from different clinical stages of adult T-Cell Leukemia. Blood 73:1664, 1989.
210. Uchiyama T, Kamio M, Kodaka T, Tamori S, Fukihara S, Amakawa R, Uchino H, Araki K: Leukemic cells from some adult T-cell leukemia patients proliferate in a response to interleukin-4. Blood 72:1182, 1988.
211. Morimoto C, Matsuyama T, Oshige C, Tanaka H, Hercend T, Reinherz EL, Schlossman SF: Functional and phenotypic studies of Japanese adult T cell leukemia cells. J Clin Invest 75:836, 1985.
212. Perri RT, Royston I, LeBien T, Kay NE: Chronic lymphocytic leukemia progenitor cells carry the antigens T65, BA-1, and Ia. Blood 61:871, 1983.
213. Baldini L, Cro L, Cortelezzi A, Calori R, Nobili L, Maiolo A, Polli E: Immunophenotypes in "classical" B-cell chronic lymphocytic leukemia: Correlation with normal cellular counterpart and clinical findings. Cancer 66:1738, 1990.
214. Brown V, Smith S, Dewart E, Maddy A: The correlation between surface immunoglobulin expression and the leucocyte-common antigen in B-cell chronic lymphocytic leukaemia. Leuk Res 11:903, 1987.
215. Roxburgh AE, Cooper IA: Expression of leukocytic-common antigen and large sialoglycoprotein on leukemic cells in B cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Leuk Res 1987:891, 1987.
216. Maddy A, Sanderson A, Mackie M, Smith S: The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia. Immunology 68:346, 1989.
217. Kraiba R, Loiseau P, Faille A, Poirier O, Piatier-Tonneau D, Degos L, Abita J, Charron D: HLA-DR and DQ antigens in chronic lymphocytic leukemia: Dissociation of expression revealed by cell surface, protein, and mRNA studies. Leukemia 3:386, 1989.
218. Inghirami G, Wieczorek R, Zhu B, Silber R, Dalla-Favera R, Knowles DM: Differential expression of LFA-1 molecules in nonHodgkin's lymphoma and lymphoid leukemia. Blood 72:1431, 1988.
219. Morabito F, Prasthofer EF, Dunlap NE, Grossi CE, Tilden AB: Expression of myelomonocytic antigen on chronic lymphocytic leukemia B cells correlates with their ability to produce interleukin 1. Blood 70:1750, 1987.
220. Medeiros LJ, Weiss LM, Picker LJ, Clayberger C, Horning SJ, Krensky AM, Warnke RA: Expression of LFA-1 in non-Hodgkin's lymphoma. Cancer 63:255, 1989.
221. Strauder R, Greil R, Schulz TF, Thaler J, Gattringer C, Radaskiewicz T, Dierich MP, Huber H: Expression of leukocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphomas and leukemias: Possible influence on growth patterns and leukemic behavior. Clin Exp Immunol 77:234, 1989.
222. Maio M, Pinto A, Carbone A, Zagonel V, Gloghini A, Marotta G, Cirillo D, Colombatti A, Ferrara F, Del Vecchio L, Ferrone S: Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood 76:783, 1990.
223. De la Hera A, Alvarez-Mon M, Sanchez-Madrid F, Marinez-A C, Durantez A: Coexpression of Mac-1 and p 150,95 on CDS+ B cells: Structural and functional characterization in a human chronic lymphocytic leukemia. Eur J Immunol 18:1131, 1988.
224. Hanson C, Gribbin T, Schnitzer B, Schlegelmilch J, Mitchell B, Stoolman L: CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood 76:2360, 1990.
225. Wormsley S, Baird S, Gadol N, Rai K, Sobol R: Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 76:123, 1990.
226. Pals ST, Horst E, Ossekoppels GJ, Figdor CG, Scheper RJ, Meijer CJLM: Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 73:885, 1989.
227. Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC: Expression of lymphocyte homing receptor antigen in nonHodgkin's lymphoma. Am J Pathol 130:496, 1988.
228. Spertini O, Freedman AS, Belvin MP, Penta AC, Yednock TA, Rosen SD, Griffin JD, Tedder TF: Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia 5:300, 1991.
229. Caligaris-Cappio F, Gobbi M, Bergui L, Campand D, Lauria F, Fierro MT, Foa R: B-chronic lymphocytic leukemia patients with stable benign disease show a distinctive membrane phenotype. Br J Hematol 56:655, 1984.
230. Woessner S, Florensa L, Besses C, Vila R, Galles C, Palou L, Sabrafen J: Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies. Leuk Res 16:505, 1992.
231. Delia D, Cattoretti G, Polli N, Fontatiella E, Aiello A, Giardini R, Rilke F, Della Porta G: CD1c but neither CD1a nor CD1b molecules are expressed on normal, activated, and malignant human B cells: identification of a new B-cell subset. Blood 72:241, 1988.
232. Orazi A, Cattoretti G, Polli N, Rilke F: CD1c and CD23 expression distinguish chronic B-lymphoctic leukemias from other chronic leukemias and leukemic lymphomas. Tissue Antigens 33:68, 1989.
233. Jones RA, Master PS, Child JA, Roberts BE, Scott CS: Diagnostic differentiation of chronic B malignancies using monoclonal antibody L161 (CD1c). Br J Haematol 71:43, 1989.
234. Catovsky D, Cherchi M, Brooks D, Bradley J, Zola H: Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 33:173, 1981.
235. Menon M, Drexler HG, Minowada J: Heterogeneity of marker expression on B-cell leukemias and its diagnostic significance. Leuk Res 10:25, 1986.
236. Tooze J, Bevan D: Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia. Clin Exp Immunol 83:423, 1991.
237. Sheibana K, Winberg CD, Van de Velde S, Blaney DW, Rappaport H: Distribution of lymphocytes with IL-2 receptors (Tac antigen) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphoma. Am J Pathol 127:27, 1987.
238. Begley C, Burton J,Tsudo M, Brownstein B, Ambrus J,Waldmann T: Human B lymphocytes express the p75 component of the interleukin 2 receptor. Leuk Res 14:263, 1990.
239. Gordon J, Mellstedt H, Aman P, Biberfield P, Bjorkkholm M, Klein G: Phenotypes in chronic B-lymphocytic leukemia probed by monoclonal antibodies and immunoglobulin secretion studies: Identification of stages of maturation arrest and the relation to clinical findings. Blood 62:910, 1983.
240. Lewandrowski K, Medeiros L, Harris N: Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype. Cancer 66:1158, 1990.
241. Karray S, Leprince C, Merle-Beral H, Debre P, Richard Y, Galanaud P: B8.7 antigen expression on B-CLL cells and its relationship to the LMW-BCGF responsiveness. Leuk Res 14:809, 1990.
242. Catovsky D, Cherchi M, Okos A, Hedge U, Galton DAG: Mouse red blood cell rosettes in B lymphoproliferative disorders. Br J Haematol 33:173, 1976.
243. Stark AN, Limbert HJ, Roberts BE, Jones RA, Scott CS: Prolymphocytoid transformation of CLL: A clinical and immunological study of 22 cases. Leuk Res 10:1225, 1986.
244. Berribi A, Dagan S, Bassous-Guedj L, Vorst E, Shtalrid M: Further characterization of prolymphocytic leukemia cells as a tumor of activated B cells. Tissue Antigens 33:324, 1989.
245. Catovsky D, Petit JE, Galetto J, Okos A, Galton DAG: The B-lymphocyte nature of the hairy cell of leukemic reticuloendotheliosis. Br J Haematol 26:29, 1974.
246. Korsmeyer SJ, Greene WC, Cossman J, Hsu SM, Jensen JP, Neckers LM, Marshall SL, Bakhshi A, Depper JM, Leonard WJ, Jaffe ES, Waldman TA: Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80:4522, 1983.
247. Divine M, Farcet JP, Gourdin MF, Tabilio A, Vasconcelos A, Andre C, Jouault A, Bouguet J, Reyes F: Phenotype study of fresh and cultured hairy cells with the use of immunologic markers and electron microscopy. Blood 64:547, 1984.
248. Anderson KC, Boyd AW, Leslie D, Fisher D, Schlossman SF, Nadler LM: Hairy cell leukemia: A tumor of pre-secretory B cells. Blood 65:620, 1985.
249. Posnett DN, Folkl RJ, Wang CY: A hairy cell leukemia associated antigen (HC2) has a distinct role in normal B cell differentiation. Leukemia 1:384, 1987.
250. Mulligan S, Travade P, Matutes E, Dearden C, Visser L, Poppema S, Catovsky D: B-ly-7, a monoclonal antibody reactive with hairy cell leukemia, also defines an activation antigen on normal CD8+ T cells. Blood 76:959, 1990.
251. Micklem K, Dong Y, Willis A, Pulford K, Visser L, Durkop H, Poppema S, Stein H, Mason D: HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the beta 7 subunit. Am J Pathol 139:1297, 1991.
252. Schwarting R, Stein H, Wang CY: The monoclonal antibodies alpha-S-HCL1(alpha-Leu-14)andalpha-S-HCL3(alpha-Leu-M5) allow the diagnosis of hairy cell leukemia. Blood 65:974, 1985.
253. Scholer Kristensen J, Ellegaard J, Hokland P: A two-colour flow cytometry assay for detection of hairy cells using monoclonal antibodies. Blood 70:1063, 1987.
254. Pandolfi F, De Rossi G, Ranucci A, Bonomo G, Pasqualetti D, Napolitano M, Manzari V: Tac-positive, HTLV-negative, Thelper phenotype chronic lymphocytic leukemia cells. Blood 65:1531, 1985.
255. Reinherz EL, Nadler LM, Rosenthal DA, Moloney WC, Schlossman SF: T cell subset characterization of human T-CLL. Blood 53:1066, 1979.
256. Baldini L, DiPadova F, Cortelezzi A, Nori A, Nobili L, Lavezzi AM, Maiolo AT, Polli EE: Functional and multimarker analysis of T cell chronic lymphocytic leukemia. Scand J Heamatol 34:88, 1985.
257. Simpkins H, Kiprov DD, Davis JL, Morand P, Puri S, Grahn EP: To cell chronic lymphocytic leukemia with lymphocytes of unusual immunologic phenotype and function. Blood 65:127, 1985.
258. Tsai LC, Tsai CC, Hyde TP, Thomas LA, Boun GO: T cell prolymphocytic leukemia with helper-cell phenotype and a review of the literature. Cancer 54:463, 1984.
259. Volk JR, Kjeldsberg CR, Eyre HJ, Marty J: T cell prolymphocytic leukemia: Clinical and immunologic characterization. Cancer 52: 2049, 1983.
260. Woods GM, Sawyer PJ, Kirow SM, Lowenthal RM, Jupe DM, Calovsky D: Functional and phenotypic analysis of a T cell prolymphocytic leukemia. Leuk Res 86:645, 1985.
261. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269, 1991.
262. Tagawa S, Tokumine Y, Ueda E, Waki K, Kanayama Y, Taniguchi N, Nakanishi T, Inoue R, Kitani T: Leu 11+ Tγ cell chronic lymphocytic leukemia with partially activated natural killer function and its further activation by recombinant IL2 in vitro. Blood 68:846, 1986.
263. Morikawa K, Oseko F, Hara J, Kobayashi S, Nakano A, Morikawa S: Functional analysis of clonally expanded CD8, TCR gamma delta T cells in a patient with chronic T-gamma lymphoproliferative disease. Leuk Res 14:581, 1990.
264. Sheridan W, Winton EF, Chan WC, Gordon DS, Volger WR, Phillips C, Bongiovanni KF, Waldman TA: Leukemia of non-T lineage natural killer cells. 1988.
265. Oshime K: Granular lymphocyte proliferative disorders: Report of 12 cases and review of literature. Leukemia 2:617, 1988.
266. Lanier L, Testi R, Bindl J, Phillips J: Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169:2233, 1989.
267. Loughran TP, Draves KE, Starkebaum G, Kidd P, Clark EA: Induction of NK activity in large granular lymphocyte leukemia: activation with anti-CD3 monoclonal antibodies. Blood 69:72, 1987.
268. Banavali S, Silvestri F, Hulette B, Hurtubise P, Srivastava A, Civin C, Preisler H: Expression of hemalopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia. Leuk Res 15:603, 1991.
269. Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF: Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 61:85, 1983.
270. Bettelheim P, Lutz D, Majdic O, Paietta E, Haas O, Linkesch W, Neumann E, Lechner K, Knapp W: Cell lineage heterogeneity in blast crises of chronic myeloid leukaemia. Br J Haematol 59:395, 1985.
271. Allouche M, Bourinbaiar A, Georgoulis V, Consolini R, Salvatore A, Auclair H, Jasmin C: T cell lineage involvement in lymphoid blast crisis of myeloid leukemia. Blood 66:1155, 1985.
272. Griffin JD, Tantravahi R, Canellos GP, Wisch JS, Reinherz EL, Sherwood G, Beveridge RP, Daley JF, Lane H, Schlossman SF: T cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood 61:640, 1983.
273. Schuh A, Sutherland D, Horsfall W, Mills G, Dube I, Baker M, Siminovitch K, Bailey D, Keating A: Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. Leukemia 4:631, 1990.
274. Maio M, Pinto A, Carbone A, Zagonel V, Gloghini A, Marotta G, Cirillo D, Colombatti A, Ferrara F, Del Vecchio L, Ferrone S: Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood 76:783, 1990.
275. Ben-Ezra J, Burke JS, Swartz WG, Brownell MD, Brynes RK, Hill LR, Nathwani BN, Oken MM, Wolf BC, Woodruff R, Rappaport H: Small lymphocytic lymphoma: A clinicophathologic analysis of 268 cases. Blood 73:579, 1989.
276. Freedman AS, Boyd AW, Berrebi A, Horowitz JC, Rosen KJ, Slaughenhoupt B, Levy D, Daley J, Levine H., Nadler LM: Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1:9, 1987.
277. Grant BW, Platt JL, Jacob HS, Kay NE: Lymphocyte populations and Tac-antigen in diffuse B-cell lymphomas. Leuk Res 10:1271, 1986.
278. Cossman J, Neckers LM, Jones T, Hsu SM, Jaffe ES: Low grade lymphomas: Expression of developmentally regulated B cell antigens. Am J Pathol 115:117, 1984.
279. Jaffe ES, Shevach EM, Frank MM, Bered CW, Green I: Nodular lymphoma - Evidence for origin from follicular B lymphocytes. N Engl J Med 290:814, 1974.
280. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, O'Hara C, Schlossman SF, Nadler LM: Expression of human B cell associated antigens on leukemias and lymphomas: A model of B cell differentiation. Blood 63:1424, 1984.
281. Picker LJ, Medeiros LJ, Weiss LM, Wamke RA, Butcher EC: Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 130:496, 1988.
282. Harris NL, Nadler LM, Bhan AK: Immunologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Am J Pathol 117:262, 1984.
283. Stein H, Gerdes J, Mason DY: The normal and malignant germinal centre. Clin Haematol 11:531, 1982,
284. Weisenberg DD, Sanger WG, Armitage JOaP D.T.: Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic findings. Blood 69:1617, 1987.
285. Weisenberg DD, Linder J, Daley DT, Armitage JO: Intermediate lymphocytic lymphoma: An immunohistologic study with comparison to other lymphocytic lymphomas. Hum Pathol 18:781, 1987.
286. Feller AC, Griesser GH, Mak T, Lennert K: Lymphoepithelioid lymphoma (Lennert's lymphoma) is a monoclonal proliferation of helper/inducer T cells. Blood 68:663, 1986.
287. Spier CM, Lippman SM, Miller TP, Grogan TM: Lennert's lymphoma, a clinicopathologic study with emphasis on phemotype and its relationship to survival. Cancer 61:517, 1988.
288. Stonesifer KJ, Benson NA, Ryden SE, Pawlinger DF, Braylan RC: The malignant cells in Lennert's lymphoma are T lymphocytes with a mature helper surface phenotype: A multiparameter flow cytometric analysis. Blood 68:426, 1986.
289. Doggett RS, Wood GS, Horning S, Levy R, Dorfman RF, Bindl J, Warnke RA: The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115:245, 1984.
290. Horning SJ, Doggert RS, Warnke RA, Dorfman RF, Cox RS, Levy R: Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood 63:1209, 1984.
291. Freedman AS, Boyd AW, Anderson KC, Fisher DC, Pinkus GS, Schlossman SF, Nadler LM: Immunologic heterogeneity of diffuse large cell lymphoma. Blood 65:630, 1985.
292. Van der Valk P, Van den Besselaar-Dingjan G, Daha MR, Meijer CJLM: Analysis of large cell lymphomas using monoclonal and heterologous antibodies. J Clin Pathol 36:44, 1983.
293. Brouet JC, Rabian C, Gisselbrecht C, Flandrin G: Clinical and immunological study of non-Hodgkin T cell lymphomas (cutaneous and lymphoblastic lymphomas excluded). Br J Haematol 57: 315, 1984.
294. Cossman J, Jaffe ES, Fisher RI: Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas: Correlations with clinical features. Cancer 54:1310, 1984.
295. Grogan TM, Fielder K, Rangel C, Jolley CJ, Wirt DP, Hicks MJ, Miller TP, Brooks R, Greenberg B, Jones S: Peripheral T cell lymphoma: Aggressive disease with heterogenous immunotypes. Am J Clin Pathol 83:279, 1985.
296. Winberg CD, Sheibani K, Krance R, Rappaport H: Peripheral T cell lymphoma: Immunologic and cell kinetic observations associated with morphologic progression. Blood 66:980, 1985.
297. Kanavaros P, Lescs M, Briere J, Divine M, Galateau F, Joab I, Bosq J, Farcet J, Reyes F, Gaulard P: Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688, 1993.
298. Williamson JM, Grigor I, Smith ME, Holgate CS, O'Brian CJ, Morgan DR, Quirke P, Alison DL, Child JA, Bird CC: Ploidy, proliferative activity, cluster differentiation antigen expression and clinical remission in high-grade non-Hodgkin's lymphoma. Histopathology 11:1043, 1987.
299. Griffith RC, Saha BK, Janney CM, Ratner L, Brunt EM, GajlPeczalska KJ, Hanto DW: Immunoblastic lymphoma of T-cell type in a chronically immunosuppressed renal transplant recipient. Am J Clin Pathol 93:280, 1990.
300. Strickler JG, Audeh MW, Copenhaver CM, Warnke RA: Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma. Cancer 61:1782, 1988.
301. Swanson S, Innes DJ, Frierson HFJ, Hess CE: T-immunoblastic lymphoma mimicking B-immunoblastic lymphoma. Arch Pathol Lab Med 111:1077, 1987.
302. Watanabe S, Sato Y, Shimoyama M, Minato K, Shimosato Y: Immunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy, and IBL-like T-cell lymphoma: A spectrum of T-cell neoplasia. Cancer 58:224, 1986.
303. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Finn T, Young L, Rowe M, Muller-Lantzsch N, Stein H: Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. Blood 78:2666, 1991.
304. Carbone A, Gloghini A, Volpe R: Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. Cancer 70:2691, 1992.
305. Miettinen M: CD30 distribution: Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas. Arch Pathol Lab Med 116:1197, 1992.
306. Shulman L, Frisard B, Antin J, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G: Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome. J Clin Oncol 11:937, 1993.
307. Kasai K, Sato Y, Kuwato S, Kawakubo Y, Inoue H, Kameya T: Sialosylated Lewis chi expression in CD30-positive anaplastic large-cell lymphomas. J Cancer Res Clin Oncol 119:87, 1992.
308. Beljaards R, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, Paulli M, Meijer C, Willemze R: Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis: A European Multicenter Study of 47 patients. Cancer 71:2097, 1993.
309. Hollema H, Poppema S: T-lymphoblastic and peripheral T-cell lymphomas in the northern part of The Netherlands: An immunologic study of 29 cases. Cancer 64:1620, 1989.
310. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE: Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A pediatric oncology group study. Blood 72:1891, 1988.
311. Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA: Lymphoblastic lymphoma: An immunophenotype study of 26 cases with comparison to Tcell actute lymphoblastic leukemia. Blood 67:474, 1986.
312. Medeiros LJ, Weiss LM, Picker LJ, Clayberger C, Horning SJ, Krensky AM, Warnke RA: Expression of LFA-1 in non-Hodgkin's lymphoma. Cancer 63:255, 1989.
313. Cossman J, Chused TM, Fisher RI, Magrath I, Bollum F, Jaffe ES: Diversity of immunological phenotypes of lymphoma. Cancer Res 43:4486, 1983.
314. Nadler LM, Reinherz EL, Weinstein HJ, D'Orsi CJ, Schlossman SF: Heterogeneity of T cell lymphoblastic malignancies. Blood 55:806, 1980.
315. Grumayer ER, Ladenstein RL, Slave I, Urban C, Radaszkiewicz T, Bettelheim P, Gadner H: B-cell differentiation pattern of cutaneous lymphomas in infancy and childhood. Cancer 61:303, 1988.
316. Sheibani K, Nathwani BN, Winberg CD, Burke JS, Swartz WG, Blayney D, van de Velde S, Hill LR, Rappaport H: Antigenically defined subgroups of lymphoblastic lymphoma: Relationship to clinical presentation and biologic behavior. Cancer 60:183, 1987.
317. Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesndo JM, Schlossman SF: Expression of common acute lymphoblastic antigen (CALLA) by lymphomas of B cell and T cell lineage. Blood 58:648, 1981.
318. Clayberger C, Medeiros LJ, Link MP, Warnke RA, Wroght A, Koller TD, Smith SD, Krensky AM: Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet 2:533, 1987.
319. Patarroyo M, Prieto J, Ernberg I, Gahmberg CG: Absence, or low expression, of leukocyte adhesion molecules CD11 and CD18 on Burkitt lymphoma cells. Int J Cancer 41:901, 1988.
320. Inghirami G, Wieczorek R, Zhu B, Silber R, Dalla-Favera R, Knowles DM: Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia. Blood 72:1431, 1988.
321. Pals ST, Horst E, Ossekoppels GJ, Figdor CG, Scheper RJ, Meijer CJLM: Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 73:885, 1989.
322. Kvaloy S, Langholm R, Kaalhus O, Michaelsen T, Funderud S, Foss E, Abrahamsen A, Godal T: Transferrin receptor and B-lymphomas antigen, their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer 33:173, 1984.
323. Salter DM, Krajewski AS, Cunningham S: Activation and differentiation antigen expression in B cell non-Hodgkin's lymphoma. J Pathol 154:209, 1987.
324. Gregory CD, Tursz T, Edward CF, Tetaud C, Talbot M, Caillou B, Rickinson AB, Lipinski M: Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol 139:313, 1987.
325. Mann RB, Jaffe ES, Braylen RC, Nanba K, Frank MM, Ziegler JL, Berard CW: Non-endemic Burkitt's lymphoma: A B cell tumor related to germinal centers. J Engl J Med 295:685, 1976.
326. Murray LJ, Habeshaw JA, Wiels J, Greaves MF: Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer 36:561, 1985.
327. Broder S, Bunn PA: Cutaneous T cell lymphomas. Semin Oncol 7:310, 1980.
328. Haynes BF, Metgar RS, Minna JD, Bunn PA: Phenotypic characterization of cutaneous T cell lymphoma: Use of monoclonal antibodies to compare with other malignant T cells. N Engl J Med 304:1319, 1981.
329. Jimbow K, Maeda K, Ito Y, Ishida O, Takami T: Heterogeneity of cutaneous T-cell lymphoma: Phenotypic and ultrastructural characterization of four unusual cases. Cancer 56:2458, 1985.
330. Nasu K, Said J, Vonderheid S: Immunopathology of cutaneous T-cell lymphoma. Am J Pathol 119:436, 1985.
331. Heald P, Yan S, Edelson R, Tigelaar R, Picker L: Skin-selective lymphocyte homing mechanisms in the pathogenesis of leukemic cutaneous T-cell lymphoma. J Invest Dermatol 101:222, 1993.
332. Sterry W, Mielke V: In reactive skin diseases and cutaneous T cell lymphomas CD4+ memory cells CD45R/2H4-, CDw29(4B4)+β, are the dominating cell type. Tissue Antigens 33:278, 1989.
333. Traweek ST, Sheibani K, Winberg CD, Mena RR, Wu AM, Rappaport H: Monocytoid B-cell lymphoma: Its evolution and relationship to other low-grade B-cell neoplasms. Blood 73:573, 1989.
334. Habeshaw JA, Lister TA, Starsfeld AG: Correlation of transferrin receptor expression with histologic class and outcome in non-Hodgkin's lymphoma. Lancet 1:498, 1983.
335. Medeiros LJ, Picker LJ, Horning SJ, Warnke RA: Transferrin receptor expression by non-Hodgkin's lymphomas. Cancer 61: 1844, 1988.
336. Holte H, De L Davies C, Kvaloy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T: The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer 39:590, 1987.
337. Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P, Foucar K, Kjeldsberg C, Levy N, Nathwani B, Schnitzer B, Tubbs R, Gaynor E, Fisher R: Prognostic significance of the Ki-67-associated proliferation antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83: 1460, 1994.
338. Cheng A-L, Chen Y-C, Wang C-H, Su I-J, Hsieh HC, Chang J-Y, Hwang W-S, Su W-C, Liu T-W, Tien H-F, Tsai W, Shen M-C, Liu C-H: Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - Should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7:725, 1989.
339. Rudders RA, DeLellis RA, Ahl ET, Bernstein S, Begg CB: Adult non-Hodgkin's lymphoma, correlation of cell surface markers phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes. Cancer 52:2289, 1983.
340. Bloomfield CD, Kersy JH, Brunning RD, Gajl-Peczalska KJ: Prognostic significance of lymphocytic surface markers in adult non-Hodgkin's malignant lymphoma. Lancet 1:1330, 1976.
341. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, Kersey JH, Goldman AI: Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. N Engl J Med 301:512, 1976.
342. Bloomfield CD, Kersey JH, Brunning RD, Gajl-Peczalska KJ: Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma. Cancer Treat Rep 61:963, 1977.
343. Levine AM, Taylor CR, Schneider DR, Koehler SC, Forman SJ, Lichtenstein A, Lukes RJ, Feinstein DI: Immunoblastic sarcoma of T-cell versus B-cell origin. I. Clinical features. Blood 58:52, 1981.
344. Coiffier B, Bryon P, Ffrench M, M. B, Sebban C, Berger F, Viala J: Intensive chemotherapy in aggressive lymphoma: Updated results of LNH-80 protocol and prognostic factors affecting response and survival. Blood 70:1394, 1987.
345. Rudders RA, Ahl Jr ET, Delellis RA: Surface marker and histopathologic correlation with long-term survival in advanced large-cell non-Hodgkin's lymphoma. Cancer 47:1329, 1980.
346. Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM: HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 82:370, 1988.
347. Spier CM, Grogan TM, Lippman SM, Slymen DJ, Rybski JA, Miller TP: The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. Am J Pathol 133:118, 1988.
348. Coiffier B, Berger F, Bryon P-A, Magaud J-P: T-cell lymphomas: Immunologic, histologic, clinical, and therapeutic analysis of 63 cases. J Clin Oncol 6:1584, 1988.
349. Horst E, Meijer CJLM, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JHJM, Pals ST: Adhesion molecules in the prognosis of diffuse large cell lymphoma: Expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 4:595, 1990.
350. Jalkanen S, Joensuu H, Klemi P: Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 75:1549, 1990.
351. Jalkanen S, Joensuu H, Soderstrom K, Klemi P: Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 87:1835, 1991.
352. Joensuu H, Ristamaki R, Klemi P, Jalkanen S: Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 68:428, 1993.
353. Strauder R, Greil R, Schulz TF, Thaler J, Gattringer C, Radaskiewicz T, Dierich MP, Huber H: Expression of leukocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphomas and leukemias: Possible influence on growth patterns and leukemic behavior. Clin Exp Immunol 77:234, 1989.
354. Jalkanen S, Aho R, Kallajoki M, Ekfors T, Nortamo P, Gahmberg C, Duijvestijn A, Kalimo H: Lymphocyte homing receptors and adhesion molecules in intravascular malignant lymphomatosis. Int J Cancer 44:777, 1989.